# What Swedish Primary Care Physicians Reported About GLP-1 Access

A 2024 survey of Swedish primary care physicians measured attitudes toward GLP-1s and reported barriers to prescribing them for obesity.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/the-doctors-agree-and-cannot-prescribe
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# What Swedish Primary Care Physicians Reported About GLP-1 Access

In an October 2024 survey, responding physicians cited limited supply and patient copayments as prescribing barriers.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Swedish primary care survey, October 2024 · agree they are effective · 98% · expect them to matter · 91% · cite supply shortages · 86% · cite patient costs · 69% · 163 responses analyzed. Response rate: 28%.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A 2024 survey asked primary care physicians in five Swedish regions about GLP-1 drugs for obesity.
-   Ninety-eight percent of analyzed respondents agreed that the drugs were effective.
-   Eighty-six percent cited availability and 69% cited patient costs as barriers.

A survey of primary care physicians in five Swedish regions recorded 190 responses in October 2024 [\[1\]](https://buythisglp.com/research/the-doctors-agree-and-cannot-prescribe#ref-1). Separate research on [barriers to getting a GLP-1 prescription](https://buythisglp.com/research/why-cant-i-get-a-glp1-prescription) considers what can prevent patients from starting. This survey asked physicians what made prescribing difficult at the time.

## What the physicians reported

The final sample of 163 respondents excludes incomplete or ineligible replies. Ninety-eight percent agreed that GLP-1 drugs were effective for treating obesity, and 91% expected them to be important in future care [\[1\]](https://buythisglp.com/research/the-doctors-agree-and-cannot-prescribe#ref-1). Low availability was cited by 86%, and high patient copayments by 69%. These percentages describe the surveyed physicians’ responses. They do not show how often patients were denied prescriptions.

## What the results can tell patients today

The survey response rate was 28%. Since [GLP-1 insurance coverage in the United States](https://buythisglp.com/research/does-insurance-cover-glp1) depends on the plan and indication, the Swedish cost figures do not predict a US copayment. The availability finding describes October 2024, when the authors reported supply shortages. Physicians who chose to respond may have differed from those who did not.

## Frequently asked

What barriers did physicians report?

Eighty-six percent cited limited drug availability and 69% cited high patient copayments. The survey was conducted in October 2024.

How many replies were analyzed?

The survey received 190 replies, a 28% response rate. Researchers analyzed 163 responses.

Does this show how many patients were denied?

The survey measured physicians’ reported barriers. It did not count denied prescriptions or observe patient outcomes.

## Sources

1.  \[1\] Sundell I, Wettermark B, Sundström A, Martinell M, Ericsson B (2026). Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey BMC Primary Care. [PMID 42557543](https://link.springer.com/article/10.1186/s12875-026-03488-y)

## Where to get it

### GLP-1 telehealth prescribers

The sellers whose own pricing describes an ongoing prescribed plan, rather than a checkout that assumes you already have a script.

[See the board →](https://buythisglp.com/best/flat-dose-pricing)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
